{
  "docId": "019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "docSlug": "7d5a5b546ee496a809a6ede1a6c2c260",
  "documentTitle": "Equillium | Investor Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 32,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "pain_points",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes a blackbox warning text block as a competitive/safety barrier context.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7b67-762e-8b55-8f35aa9a2cc0/25",
  "deckHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "deckJsonHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0.json",
  "deckAnchorHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "callout",
      "text": "EQ101 is positioned as a well-tolerated and effective alternative to JAK inhibitors",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0273bf4-316b-4e41-9f93-cd8b609f2b52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.25,
        "x": 0.48,
        "y": 0.31
      },
      "kind": "chart",
      "text": "I am concerned about the safety of oral JAK inhibitors for my AA patients. % of respondents, n = 101",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1a8698f-e7aa-45dc-b37e-6391e1a367ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.03,
        "y": 0.31
      },
      "kind": "list",
      "text": "Currently approved and late-stage pipeline drugs are all JAK inhibitors. There remains a chronic need, without a safe chronic treatment. Dermatologists indicate safety concerns are the primary barriers to JAKi use in AA patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26d39276-1abc-4b18-b74b-2ae519504173",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.42,
        "x": 0.03,
        "y": 0.65
      },
      "kind": "metric",
      "text": "79% of physicians surveyed, believe there is an extremely high unmet medical need*",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32111504-1ac9-4dde-aa5a-3326109c0875",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.21,
        "x": 0.76,
        "y": 0.31
      },
      "kind": "paragraph",
      "text": "Blackbox warning: WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52a8f1fd-c847-49a0-9c55-a02f20d8e28f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "* Spherix Global Insights; ** Olumiant Package Insert",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3cd09e93-9680-43b6-9799-3a41a930e485",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Large Unmet Need in Alopecia Areata",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9954ffc-c425-47cf-9922-8d66671e25c4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 25,
      "beatId": "8c481ac3-672a-40eb-b1e3-cc8ba774a1a5",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slide 25 emphasizes the large unmet need in Alopecia Areata, making the problem worse and highlighting the need for better solutions.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 25,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a8c47462-fc5b-49e1-9612-5ff095e540ec",
      "evidence": "Slide 25 emphasizes the large unmet need in Alopecia Areata, implying the cost of inaction.",
      "position": 0,
      "objective": "Highlight the cost of inaction in addressing Alopecia Areata",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}